Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price cut by investment analysts at Citigroup from $173.00 to $170.00 in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective would suggest a potential upside of 56.54% from the stock’s current price.

A number of other equities analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. TheStreet lowered shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Robert W. Baird upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price objective on the stock in a research report on Monday, December 18th. Royal Bank of Canada lifted their price objective on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $170.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $153.14.

Alexion Pharmaceuticals (NASDAQ ALXN) opened at $108.60 on Friday. The company has a current ratio of 3.10, a quick ratio of 2.51 and a debt-to-equity ratio of 0.34. The stock has a market cap of $24,260.00, a P/E ratio of 55.13, a PEG ratio of 0.91 and a beta of 1.16. Alexion Pharmaceuticals has a 1 year low of $96.18 and a 1 year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. The business had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $1.26 earnings per share. research analysts predict that Alexion Pharmaceuticals will post 6.25 EPS for the current year.

In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 1,261 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $147,864.86. Following the sale, the executive vice president now directly owns 20,210 shares in the company, valued at approximately $2,369,824.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the sale, the chief executive officer now owns 36,172 shares in the company, valued at $4,399,600.36. The disclosure for this sale can be found here. Insiders have sold a total of 28,930 shares of company stock worth $3,378,199 over the last 90 days. Insiders own 4.35% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Valeo Financial Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth $147,000. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth $156,000. BT Investment Management Ltd purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth $165,000. Beacon Investment Advisory Services Inc. purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth $201,000. Finally, Invictus RG purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth $202,000. Institutional investors own 94.04% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Price Target Cut to $170.00” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://theolympiareport.com/2018/02/11/alexion-pharmaceuticals-alxn-price-target-cut-to-170-00.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.